The company has started the trial of SCI-210 to treat Autism Spectrum Disorder symptoms in children. Credit: Ground Picture / Shutterstock.com.

SciSparc has commenced the clinical trial of its new therapy, SCI-210, to treat ASD symptoms in children.

ASD differs widely among those it affects, presenting challenges in social interaction and communication.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The double-blind, randomised and placebo-controlled study has been initiated at the Soroka Medical Center in Israel.

SCI-210 is a combination of cannabidiol (CBD) and SciSparc’s Palmitoylethanolamide, designed to alleviate ASD symptoms.

SciSparc will enrol 60 subjects aged between five and 18 years over 20 weeks for scientifically measuring how the therapy compares to standard CBD treatment in managing symptoms of ASD.

See Also:

SciSparc CEO Oz Adler said: “Our pioneering treatment aims to reduce and alleviate the symptoms of autism along with reducing the side effects that are common when taking cannabis-based treatments, such as CBD.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“Partnering with the Soroka Medical Center and the National Autism Research Center, we are exploring new territory in ASD treatment.

“We are driven by science and the goal of improving life quality for children with ASD and their families.”

During this month, SciSparc started a Phase IIb clinical study of SCI-110 to treat patients with Tourette Syndrome.

The study is being conducted under the regulation of the US Food and Drug Administration (FDA), the Israeli Ministry of Health, and the Federal Institute for Drugs and Medical Devices in Germany.

The company commenced the trial at the Tel Aviv Sourasky Medical Center and is anticipated to continue with its medical sites in Germany and the US.